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Abstract
Adipose-derived stem/stromal cells (ASCs) are progenitor cells used in bone tissue engineering and regenerative
medicine. Since Bichat’s fat pad is easily accessible for dentists and maxillo-facial surgeons, we compared the fea-
tures of ASCs from Bichat’s fat pad (BFP-ASCs) with human ASCs from subcutaneous adipose tissue (SC-ASCs).
BFP-ASCs isolated from a small amount of tissue were characterized for their stemness and multidifferentiative
ability. They showed an important clonogenic ability and the typical mesenchymal stem cell immunophenotype.
Moreover, when properly induced, osteogenic and adipogenic differentiation markers, such as alkaline phospha-
tase activity, collagen deposition and lipid vacuoles formation, were promptly observed. Growth of both BFP-
ASCs and SC-ASCs in the presence of human serum and their adhesion to natural and synthetic scaffolds
were also assessed. Both types of ASCs adapted rapidly to human autologous or heterologous sera, increasing
their proliferation rate compared to standard culture condition, and all the cells adhered finely to bone, periodon-
tal ligament, collagen membrane, and polyglycol acid filaments that are present in the oral cavity or are com-
monly used in oral surgery. At last, we showed that amelogenin seems to be an early osteoinductive factor for
BFP-ASCs, but not SC-ASCs, in vitro. We conclude that Bichat’s fat pad contains BFP-ASCs with stemness features
that are able to differentiate and adhere to biological supports and synthetic materials. They are also able to pro-
liferate in the presence of human serum. For all these reasons we propose BFP-ASCs for future therapies of peri-
odontal defects and bone regeneration.
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Introduction
Mesenchymal stem/stromal cells (MSCs) representimportant suitable candidates in regenerative medicine
applications for the treatment of tissues damaged by trauma
or pathological diseases. They have been isolated from bone
marrow, adipose tissue, tendon, periodontal ligament, syno-
vial membranes, trabecular bone, skin, periostium, and mus-
cle.1 Even though bone marrow represents the more used
source of stem cells (BMSCs) in the clinical field, adipose tis-
sue is a valid alternative source of MSCs. It is easily accessible
in large quantities with a minimal invasive harvesting proce-
dure and allow a high number of adipose-derived mesenchy-
mal stem/stromal cells (ASCs) to be obtained.2,3 ASCs show
a multilineage differentiation capacity similar to that of
BMSCs.4–6 The growth factor secretome of MSCs was charac-
terized by Wang et al.,7 and the secretory activity of MSCs
favors a regenerative microenvironment at sites of tissue
injury.8
Adipose tissue withdrawn during plastic surgery is a dis-
carded tissue, and the usual anatomical regions from which
this tissue is collected are the abdomen, breast, buttock,
knee, and thigh. In this study, we have characterized
human ASCs isolated from the buccal fat pad, usually called
Bichat’s fat pad (BFP), one of the encapsulated fat masses in
the cheek. It is a deep fat pad located on either side of the
face between the buccinator muscle and several more super-
ficial muscles, including the masseter, the zygomaticus major,
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and the zygomaticus minor.9,10 Several authors described the
buccal fat pad functions in relation to mastication and suc-
tion.9 This tissue can usually be easily harvested with mini-
mal discomfort and complications for patients and is used
in facial reconstruction.11–13 Removal of the buccal fat pad
is also sometimes done to reduce cheek prominence, although
this procedure may carry with it a significant risk of damage
to the buccal branch of the facial nerve and the parotid
ducts.14 The buccal fat pad flaps are used in the reconstruc-
tion of the periorbital area,15 for the repair of congenital
oro-antral and/or oro-nasal disorders,16 and for congenital
cleft palate repair.17 More recently, they have also been
used for the closure of oro-antral communications18,19 and
treatment of oral submucous fibrosis,20,21 intraoral malignant
defects,22 and cheek mucosa defects.23
The aim of this study was to isolate, characterize, and com-
pare human ASCs isolated from the buccal fat pad and sub-
cutaneous fat regions, and to highlight a new source of
more accessible ASCs for use in periodontal, oral implant,
and maxillo-facial surgery. Moreover, we evaluated the adhe-
sion of hASCs on resorbable materials and the effect on these
progenitor cells by amelogenin (AM)–enamel matrix deriva-
tive, a porcine matrix protein used to treat periodontal defects
on natural teeth.24–26
Materials and Methods
Patient enrollment
Adipose tissues were harvested from dental patients se-
lected by using the clinical criteria reported in Table 1. The en-
rolled patients (1 man and 1 woman, n = 2, age 35.5 – 2.7
years) were in good health without any systemic complica-
tions. The informed consent and experimental protocols for
this study were reviewed and approved after written consent
by the Ethics Committee and Institutional Review Board of
University of Milan (authorization #17/12 of April 23, 2012).
Local anesthesia was performed (carbocaine 2% and adren-
aline 1:100,000) either in the oral cavity or in the subcutaneous
fat tissue; the surgical access for liposuction was performed at
the navel using the lipofilling technique: fat was harvested
with a sterile 10-mL BD Luer Lock syringe performing a con-
stant manual negative pressure (plunger positioned between
1 and 2 mL).27,28
The tooth was extracted and different tissues were collect-
ed: alveolar bone, as a result of modeling the residual extrac-
tion socket; periodontal ligament; and tooth portions, coronal
and root. Finally, BFP was approached, cutting the mucosa in
proximity to the second molar teeth, 0.5 cm from the fornix.
Blunt dissection was performed to prevent damage, to close
the anatomical structures, and to allow the identification
and exteriorization of the fat pad. BFP was stretched into
the wound to close the residual defect and extra tissue was
cut (Fig. 1). This technique is widely used either for aesthetic
or reconstructive reasons.29,30 At the end of the procedure,
Ethilon 5.0 sutures were used to close the surgical access.
Table 1. Enrollment Criteria for Patients
Clinical inclusion criteria:
 Patients classified as ASA I–II
 Males and females, between 18 and 70 years of age, with
compromised wisdom teeth and thin bone at the
maxillary sinus
 Possibility of withdrawing subcutaneous adipose tissue
from abdominal region at the same time
Clinical exclusion criteria:
 Disorders of the parotid glands
 Disorders affecting fat and carbohydrate metabolism
 Presence of adequate bone support under remaining teeth
 No risk of oro-sinusal communication after tooth
extraction
 Medical contraindications to elective surgery
FIG. 1. Extraction of Bichat’s
fat pad (BFP). (a) Preoperative
conditions. Poor oral hygiene;
26 compromised by periodon-
tal disease, absence of 27, and
caries infiltrating 28. (b)
Exposure of BFP. (c) Tunnel-
ing and positioning of the BFP
to repair defect. (d) Waste
material of the BFP at the end
of surgery.
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Patients’ blood was also collected, and all the specimens were
sent to the laboratory.
One day before surgery, patients were treated with amox-
icillin (1 g twice a day) to prevent bacterial load, and this ther-
apy was maintained for additional 5 days. Sutures were
removed after 1 week and the patients were monitored at 2
weeks and at 1 and 6 months.
The pain was controlled for 2 days with naproxen (550 mg
twice daily). A mild muscle contraction lasting 4 days was ob-
served in one patient; no other complications were described,
and after 2 weeks the tissues were already well-epithelized.
Isolation and characterization of ASCs
Isolation and culture. Subcutaneous adipose tissues were
obtained from buccal fat pad (BFP-ASCs) and abdominal sub-
cutaneous tissue (SC-ASCs). ASCs were isolated as previ-
ously described.6 The tissues were enzymatically digested
by 0.075% type I collagenase for 30 min at 37C. The stromal
vascular fraction was obtained by centrifugation at 1200 g for
10 min, filtered through a sterile medication lint, and plated
(105 cells/cm2) in the cDMEM control (CTRL) medium, com-
posed of Dulbecco’s modified Eagle’s medium (DMEM;
Sigma-Aldrich, Milan, Italy) supplemented with 10% fetal
bovine serum (FBS), 50 U/mL penicillin, 50 lg/mL strepto-
mycin, and 2 mM L-glutamine (Sigma-Aldrich). Cells were
then maintained at 104 cells/cm2.
Proliferation. Both cell types were maintained in culture
for 21 days and counted every week. The doubling time
was calculated as (ln [N/N0])/(ln 2), where N is the number
of the counted cells and N0 represents the number of plated
cells.
MTT assay for cell viability. From passage 4 to 7, ASC vi-
ability was monitored at day 1 and 7. Cells were incubated for
4 h at 37C with 0.5 mg/mL of 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) in
CTRL medium. Viable cells produced formazan precipitate,
which was then solubilized in 100% dimethylsulfoxide
(DMSO; Sigma-Aldrich). The absorbance was read at
570 nm with the Wallac Victor II plate reader (Perkin Elmer
Western Europe, Monza, Italy).
Colony forming unit–fibroblast assay. ASCs were plated
in DMEM supplemented with 20% FBS, 50 U/mL penicillin,
50 lg/mL streptomycin, and 2 mM L-glutamine in six-well
plates by serial dilution starting from 1000 cells/well.
Medium was changed after 6 days, and at day 14 cells were
fixed in 100% methanol and stained with 0.5% crystal violet
(Fluka, Buchs, Switzerland). Individual colonies (consisting
of at least 25 cells) were counted, and the colony forming
unit–fibroblast (CFU-F) frequency was calculated with re-
spect to the number of seeded cells.
Flow cytometry analysis. ASCs (3 · 105) in PBS with 1%
FBS/0.1% NaN3 per sample were incubated for 30 min on ice
with monoclonal antibodies raised against CD14, CD31
CD34, CD73, CD90, and CD105 (Ancell, Bayport, MN). Specific
binding was revealed by either streptavidin-PE– or fluores-
cein isothiocyanate–conjugated sheep anti-mouse antibody.
Samples were acquired by FACS Calibur flow cytometer (BD
Biosciences Europe, Erembodegem, Belgium) and data were
analyzed using CellQuest software (BD Biosciences Europe).
Assessment of multidifferentiative potential
of BFP- and SC-ASCs
Adipogenic differentiation. ASCs (104/cm2) were induced
to differentiate towards the adipogenic lineage culturing them
for 14 days in cDMEM supplemented with 1lM dexametha-
sone, 10lg/mL insulin, 500lM 3-isobutyl-1-methyl-xanthine,
and 200lM indomethacin (induction medium, Sigma-Aldrich).
Then, cells were fixed in 10% neutral buffered formalin for 1 h
and stained by fresh Oil Red O solution (20 mg/mL [w/v] Oil
Red O in 60% isopropanol) for 15 min. Lipid vacuoles were
quantified by extraction with 100% isopropanol for 10 min
and reading the absorbance at 490 nm with the Wallac Victor
II plate reader.
Osteogenic differentiation. ASCs (104/cm2) at passage 7
were cultured for 14 days in CTRL and osteogenic inductive
medium (OSTEO; 10 nM dexamethasone, 10 mM glycerol-2-
phosphate, 150lM L-ascorbic acid-2-phosphate, and 10 nM
cholecalciferol [Sigma-Aldrich] added to cDMEM). To evalu-
ate alkaline phosphatase (ALP) enzymatic activity, both un-
differentiated and differentiated ASCs were lysed in 0.1%
Triton X-100 and incubated at 37C with 10 mM p-nitrophe-
nylphosphate dissolved in 100 mM diethanolamine and
0.5 mM MgCl2, pH 10.5.
31 Samples were read at 405 nm and
ALP activity was calculated with respect to the protein con-
centration of each sample determined by BCA Protein
Assay (Pierce Biotechnology, Rockford, IL).
To determine collagen production, ASCs were fixed for 1 h
with Bouin’s solution (Sigma-Aldrich) and then stained for
1 h with 1 mg/mL (w/v) Sirius Red F3BA in saturated picric
acid (Sigma-Aldrich). Stained samples were extracted with
0.1 M NaOH for 5 min and then read at 550 nm.32
Proliferation of ASCs in the presence of human sera
Serum collection. Ten milliliters of blood were collected
from each donor, allowed to clot for 30–45 min at 37C and
then transferred at 4C for 30 min. After centrifugation
(1000 g for 10 min) the sera were carefully removed and
placed in new 15-mL tubes. All sera were collected under ster-
ile conditions.33
Cell culture. ASCs (6 · 104/well) were cultured in six-
well plates in DMEM supplemented with either 10% or 5%
autologous serum (HAS) or 5% heterologous serum (HHS).
ASCs were also grown in cDMEM as control medium. Cells
were cultured for four passages; they were detached and
replated every 5 days and counted each time.
ASCs-scaffold interaction and scanning
electron microscopy
ASCs (1·105 and 3·104) were grown for 4 days on natural
supports (alveolar bone and periodontal ligament) and on syn-
thetic scaffolds (collagen membrane; Euroresearch, Milan, Italy
and polyglycol acid filaments; Resorb, Sweden and Martina,
Padova, Italy), respectively. The constructs were fixed in glutar-
aldehyde (2% in 0.1 M sodium cacodylate buffer) overnight at
4C and dehydrated with a series of graded ethanol (from
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75% to 100%) for 4–5 h at room temperature and subjected to
drying using critical point drying (CPD; Baltec C.P.D. 030).
Samples were mounted on aluminum stubs, sputter-coated
with gold (Balzers MED 010) and analyzed by scanning electron
microscopy (SEM; Sem Quanta Feg 250 esem).
Amelogenin and BFP- and SC-ASCs
Both types of ASCs were cultured for 7 days in the pres-
ence of AM (Emdogain, Straumann, Basel, Switzerland).
ASCs (1.5 · 104/well) were seeded in a 24-well culture
plate, with wells previously spread with a drop of AM, and
cultured in either cDMEM or osteogenic medium. ALP activ-
ity and collagen deposition were evaluated as previously de-
scribed. As control, we considered ASCs cultured in the
absence of AM.
Statistical analysis
Data are expressed as mean– standard deviation. Statisti-
cal analyses were performed using Student t-test. Differences
were considered significant at p< 0.05.
Results
Characterization of human ASCs derived from the BFP
In this preliminary study, we analyzed cell populations de-
rived from two donors who were enrolled for surgery for
upper wisdom tooth extraction with sinus communication
(Fig. 1). MSCs were isolated from both adipose tissue of
BFP (BFP-ASCs, n = 2) and abdominal subcutaneous tissue
(SC-ASCs, n = 2). We collected 0.8 – 0.4 mL of BFP and
37.0 – 32.5 mL of subcutaneous adipose tissue; despite the
different amount of raw adipose tissues, we isolated a quite
similar amount of cells per milliliter (1.1 · 105 – 1.4 · 104
BFP-ASCs/mL and 1.15·105–7.1·103 SC-ASCs/mL; Table 2).
The BFP-ASCs were characterized for their immunopheno-
type; a representative cytofluorimetric analysis of both BFP-
ASCs and SC-ASCs is shown in Figure 2. Cells appeared to
have similar granularity but were different in size (Fig. 2).
Both types of ASCs isolated expressed the characteristic
stem cell markers such as CD73, CD90, and CD105, whereas
they did not express lymphocyte or leucocyte antigens and
hematopoietic markers such as CD14, CD31, and CD34
(Fig. 2).
One week after isolation, ASC populations begin to prolif-
erate and, after 21 days, starting from 6· 104 ASCs,
5.9 · 105 – 2.6 · 105 BFP-ASCs and 1.3 · 106 – 3.0 · 105 SC-
Table 2. Volume of Adipose Tissue and Cellular
Yield of Adipose-Derived Stem/Stromal Cells
Derived From Bichat’s Fat Pad
and Subcutaneous Adipose Tissue
Sample Volume (mL) ASCs/mL of adipose tissue
BFP-ASCs-1 1 1.0 · 105
BFP-ASCs-2 0.5 1.2 · 105
SC-ASCs-1 60 1.2 · 105
SC-ASCs-2 14 1.1 · 105
ASCs, adipose-derived stromal/stem cells; BFP, derived from
Bichat’s fat pad; SC, derived from subcutaneous adipose tissue.
FIG. 2. A representative FACS analysis of BFP-ASCs-1 (a) and SC-ASCs-1 (b) stained for CD73, CD90, CD105, CD14, CD31,
and CD34. Size and granularity are shown (top).
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ASCs were collected (Fig. 3a); indeed, SC-ASCs proliferated
faster than BFP-ASCs, with an average doubling time of
73.5 – 17.2 h compared to 126.5– 33.6 h (data not shown).
This was also confirmed through a viability test, in which
MTT incorporation by SC-ASCs-1 and -2, was mildly higher
than that of BFP-ASCs (Fig. 3b). Another observed small
difference, as shown in Figure 3c, concerns cellular morphol-
ogy: SC-ASCs appeared to be a homogeneous population,
with the distinctive fibroblast-like shape maintained for
long time in culture (Fig. 3c, right), whereas BFP-ASCs, as
FIG. 3. Comparison of
BFP-ASCs-1, -2 (left), and
SC-ASCs-1, -2 (right). (a) Cell
number of ASCs cultured for
21 days. (b) Viability of ASCs
monitored for 1 week in
cDMEM and tested as MTT
metabolic activity. (c) Mor-
phology of BFP-ASCs and SC-
ASCs (optical microscopy,
100· and 400 · magnifica-
tion, scale bar 100 lm). (d)
Clonogenicity of both ASCs by
CFU-F assay. Percentage of
CFU-F was calculated as
number of colonies/number
of plated cells · 100. ASCs,
adipose-derived stem/
stromal cells; SC, subcutane-
ous; cDMEM, Dulbecco’s
modified Eagle’s medium
(DMEM) supplemented with
10% fetal bovine serum (FBS),
50 U/mL penicillin, 50lg/mL
streptomycin, and 2 mM
L-glutamine; CFU-F, colony-
forming unit–fibroblast.
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previously shown in Figure 2, appeared slightly smaller and
rounder compared with SC-ASCs (Fig. 3c, left).
Surprisingly, BFP-ASCs, and in particular BFP-ASCs-2,
showed a noticeable clonogenic ability respect to the two
populations of SC-ASCs (Fig. 3d), with an average of about
9.2% – 4.5% BFP-ASCs able to produce CFU-F from passage
2 to 4 (Fig. 3d). Interestingly, BFP-ASCs-1 showed a signifi-
cant increase in colony formation at late passages (from pas-
sage 7 to 9, + 19.1% – 7.7%; data not shown), suggesting a
delayed selection of progenitor cells.
No significant difference between BFP-ASCs and SC-ASCs
from the two donors was observed.
Differentiation of human BFP-ASCs
Adipogenic differentiation. After 2 weeks in the presence
of adipogenic stimuli, an important morphological change
was induced compared to undifferentiated cells (CTRL;
Fig. 4a) The classic fibroblast-like shape of human ASCs
was lost, and both ASC populations showed lipid vacu-
oles–enriched cytoplasm (Fig. 4a). A considerable produc-
tion of lipid vacuoles was observed in differentiated
BFP-ASCs (Fig. 4b, left) and SC-ASCs (Fig. 4b, right); how-
ever, no difference was observed in the adipogenic poten-
tial of ASCs derived from the two anatomical regions
( p < 0.05).
Osteogenic differentiation. After 14 days of osteogenic
induction (OSTEO), both BFP-ASCs and SC-ASCs showed
a significant up-regulation of two specific markers, ALP
activity and collagen deposition (Fig. 5). The two differenti-
ated BFP-ASCs populations significantly up-regulated their
ALP levels with respect to undifferentiated cells, with
an increase of 504.0% and 334.1% for BFP-ASCs-1 and
BFP-ASCs-2, respectively (Fig. 5a, left). The osteogenic abil-
ity of SC-ASCs is also reported in Figure 5a (right), which
shows that the ALP activity of osteo-differentiated SC-
ASCs was significantly augmented, with an increase of
about 620% and 486%, for SC-ASCs-1 and SC-ASCs-2,
respectively.
OSTEO-BFP-ASCs-1 and -2 produced a considerable
amount of collagen, with an average increase of 100% and
49%, respectively, compared to undifferentiated cells (Fig.
5b, left). High levels of collagen were also produced by
osteo-differentiated SC-ASCs-1 and -2, with an increase of
129% and 146%, respectively, compared to undifferentiated
cells (Fig. 5b, right). Figure 5c shows both BFP-ASCs and
SC-ASCs, maintained for 14 days in both CTRL and
OSTEO, fixed and stained by Sirius-Red.
Growth of ASCs with human sera
Considering a possible future clinical application, we stud-
ied the ability of BFP-ASCs and SC-ASCs to grow in me-
dium supplemented with human serum. Both populations
were cultured in the presence of 10% or 5% HAS or 5%
HHS, and their growth was compared to that of cells main-
tained in standard conditions (10% FBS). No differences in
morphology were observed. In all the growth conditions,
the ASC populations maintained the fibroblast-like shape
(Fig. 6a, b), and their proliferation rate was analyzed at 7,
14 (Fig. 6c, d), and 21 days of culture. The presence of 10%
HAS induced a prompt increase (within 7 days) in both
BFP-ASC and SC-ASC numbers compared to other sera
(Fig. 6c, d). The superior proliferation rate was quite evident
for both cell types after 21 days of culture (8.5 · 106 – 6.9 · 106
BFP-ASCs and 5.4 · 106– 7.6 · 105 SC-ASCs; data not shown),
whereas cells cultured in the presence of 5% HAS and 5%
HHS showed a comparable trend of cellular growth with
those cultured under standard conditions (Fig. 6c, d).
Human ASCs and scaffolds
The ability of ASCs to adhere to and grow on the types of
scaffolds routinely applied in periodontal and oral bone re-
generation was tested by seeding them on natural and syn-
thetic biomaterials such as bone, periodontal ligament,
collagen membrane, and polyglycol acid filaments. Undiffer-
entiated BFP-ASCs and SC-ASCs were first loaded and then
cultured on the scaffolds for 4 days, as shown in Figure 7.
Both cell types adhered to the natural supports nicely. The
FIG. 4. Adipogenic differen-
tiation. (a) Microphotographs
of BFP-ASCs and SC-ASCs
maintained for 14 days in
control (CTRL) and adipo-
genic medium (ADIPO; 200 ·
magnification, scale bar
50 lm); lipid vacuoles are
positively stained by Oil Red
O. (b) Quantification of lipid
vacuole formation in CTRL
(white bars) and ADIPO (grey
bars) BFP-ASCs-1, -2 and
SC-ASCs-1, -2. ADIPO vs.
CTRL: **p < 0.01, ***p< 0.001.
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only slight difference observed was when cells were kept on
suture filaments of polyglycolic acid, on which BFP-ASCs did
not seem to be tightly bound.
Amelogenin as an osteogenic inductive factor in vitro
In a preliminary experiment BFP-ASCs and SC-ASCs were
cultured for 7 days in the presence of 3% AM. This molecule
was able to increase ALP activity, both in undifferentiated
and OSTEO-differentiated BFP-ASCs. This effect was ob-
served primarily with BFP-ASCs rather than with SC-ASCs,
suggesting that the former were more sensitive. In particular,
ALP activity was stimulated by AM with an increase of*220%
in undifferentiated cells (/+ ), and further up-regulated when
BFP-ASCs were OSTEO-differentiated (+/+ ), suggesting a
synergic effect ( + 950.4; Fig. 8a, b). Collagen deposition was
also up-regulated about 32.5% for both OSTEO-differentiated
ASCs (Fig. 8c, d).
FIG. 6. ASCs cultured in
DMEM supplemented with
human sera. Microphoto-
graphs (100 · magnification,
scale bar 100 lm) of BFP-
ASCs-1 (a) and SC-ASCs-1 (b)
maintained for 14 days in
DMEM in the presence of 10%
or 5% autologous serum
(HAS), 5% heterologous
serum (HHS) and 10% FBS.
Number of BFP-ASCs (b; n = 2)
and SC-ASCs (c; n = 2) were
counted at day 0, 7, and 14 of
culture. Data are expressed as
mean – SD. 10% HAS vs. 5%
HHS: *p< 0.05; 10% HAS vs.
10% FBS: xp< 0.05.
FIG. 5. Osteogenic differentiation. (a) Alkaline
phosphatase (ALP) activity of undifferentiated
(CTRL, white bars) and osteo-differentiated
(OSTEO, grey bars) BFP and SC-ASCs-1, -2 at
passage 7. Data are normalized vs. protein con-
centrations of each sample. (b) Quantification of
collagen deposition in CTRL and OSTEO BFP and
SC-ASCs-1, -2 at passage 7. OSTEO vs. CTRL:
*p< 0.05, **p < 0.01, ***p< 0.001. (c) Representative
images of collagen production by BFP-ASCs and
SC-ASCs cultured for 14 days in CTRL and
OSTEO media and stained with Sirius Red S.
MESENCHYMAL STEM CELLS FROM BICHAT’S FAT PAD 113
Discussion
In order to characterize a new source of MSCs, we evalu-
ated human ASCs isolated from the BFP, comparing them
with the ones isolated from subcutaneous adipose tissue.
Since the final purpose will be the use of these cells for a fu-
ture therapy of periodontal defects and bone regeneration,
we also studied their differentiative ability and their growth
on different substrates.
It is feasible to isolate a proper quantity of stem cells even
by starting from a small amount of raw adipose tissue (0.5–
1 mL) such as BFP. As previously reported for ASCs isolated
from subcutaneous tissue,6,34 we found that BFP-ASCs also
share MSC features. In fact, their typical fibroblast-like mor-
phology was present in both populations even though BFP-
ASCs appeared to have a smaller and rounder cell body.
Moreover, the immunophenotype and the clonogenic activity
confirmed their stemness; interestingly, BFP-ASCs were even
more prone to produce colonies than SC-ASCs. Both cell
types are multipotent and they can be induced to differenti-
ate, as previously described by Farre´-Guasch et al.35 In partic-
ular, we observed the production of lipid vacuoles and an up-
regulation of ALP activity and collagen deposition already
after 14 days of induced differentiation in vitro. In our exper-
imental conditions, differentiation was detected in the ab-
sence of bone morphogenic proteins, which seemed to be
necessary in the study of Shiraishi et al.36 This could be due
either to the different osteogenic media used or to the possible
variability among cells derived from healthy donors of our
study and the patients with jaw deformity of theirs.
Since our data seem to support future tissue-engineering
applications, we investigated the behavior of BFP-ASCs in as-
sociation either with natural supports, such as bone and peri-
odontal ligament or biocompatible materials that might be in
contact with these cells in a clinical setting. It is known that
SC-ASCs can be successfully seeded on demineralized and
decellularized bone;37–39 here, we also showed a stable inter-
action of SC-ASCs and BFP-ASCs with healthy tissues such as
autologous alveolar bone and periodontal ligament. More-
over, all the cells also efficiently adhered to collagen mem-
brane and polyglycol acid filaments, two materials chosen
for their resorbable property and the widespread use in sur-
gery. This noted adaptability of ASCs, to survive and grow
on all supports assayed and present during oral surgery,
represents a prominent quality for a future regenerative-
medicine approach. Interestingly, one of our experiments
indicated that osteo-differentiation of BFP-ASCs is specifi-
cally induced and up-regulated by AM, as also previously
reported for BMSCs.40–42 AM is the most abundant enamel
matrix protein and dentists favor it for the repair of periodon-
tal defects. The success of this treatment depends on which
cell line fills the defect; in particular, it is important to pro-
mote the growth of periodontal ligament cells and slow that
of gingival and epithelial cells to let the correct cells prolifer-
ate close to the dental root. AM enhances the proliferation of
periodontal MSCs that secrete cytokines and cause the syn-
thesis of new cementum and periodontal fibers. Subse-
quently, the regeneration of the periodontium creates the
precondition for new formation of functional attachment
and for bone regeneration.24 A recent review by Bosshardt43
also sheds light on other biological mechanisms of this com-
pound that seems to affect a great variety of cells types in-
cluded MSCs, pre-osteoblasts, and osteoblasts, influencing
their proliferation, expression of transcription factors and cy-
tokines, and their differentiation, showing the direct influence
of AM on bone regeneration. Our experimental approach
showed the effect of AM on osteogenic differentiation of
human ASCs with a synergic effect with others osteo-induc-
tive factors. We may assume that this synergy, observed
in vitro, could be maintained in vivo, where a lot of growth
and differentiation factors are released during the fracture
healing.44 Moreover, this effect is more evident for BFP-
ASCs than for SC-ASCs, possibly due to the natural locali-
zation of BFP-ASC that could make them more prone to
respond to stimuli naturally secreted in the same body area.
Since it was already reported that culturing ASCs with au-
tologous serum does not negatively affect them45,46 and with
FIG. 7. Undifferentiated BFP-ASCs (left) and SC-ASCs
(right) maintained on natural and synthetic scaffolds for 4
days. Bone fragment (scale bar, 10 lm), periodontal ligament
(scale bar, 20 lm), collagen membrane (scale bar, 50 lm), and
polyglycol acid (scale bar, 30 lm) are shown.
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prospective clinical applications, we cultured these cells in
self and nonself conditions. We noticed that the presence of
human serum enhanced the proliferation rate of both cells
types. This effect has not been previously observed on
ASCs, but similar heterogeneity in the response to autologous
sera has been also described for bone marrow stem cells47–50
and could be explained by the differences of sera from the do-
nors. Growing ASCs in the presence of autologous serum
could be a convenient and safe procedure in future cellular
therapy, eliminating the concerns about contact with animal
proteins.
We conclude that ASCs can be isolated from small speci-
mens such as BFP; their features and behavior are quite sim-
ilar to the most known SC-ASCs. BFP-ASCs are sensitive
to the classical osteo-differentiative stimuli but also, quite
interestingly, to AM. We believe that these results are very
encouraging, although further experiments are required
to confirm the effect of AM on progenitor cells derived
from BFP.
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